Nicholas A. Kennedy

List of Publications by Year
in descending order

116 papers	8,680 citations	76326 40 h-index	49909 87 g-index
122 all docs	122 docs citations	122 times ranked	12545 citing authors

#	Article	IF	Citations
1	British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut, 2019, 68, s1-s106.	12.1	1,353
2	Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nature Genetics, 2017, 49, 256-261.	21.4	943
3	Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet, The, 2016, 387, 156-167.	13.7	607
4	Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. The Lancet Gastroenterology and Hepatology, 2019, 4, 341-353.	8.1	431
5	Beyond Gene Discovery in Inflammatory Bowel Disease: The Emerging Role of Epigenetics. Gastroenterology, 2013, 145, 293-308.	1.3	275
6	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohnâ€™s Disease. Gastroenterology, 2020, 158, 189-199.	1.3	249
7	The Impact of Different DNA Extraction Kits and Laboratories upon the Assessment of Human Gut Microbiota Composition by 16S rRNA Gene Sequencing. PLoS ONE, 2014, 9, e88982.	2.5	236
8	Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut, 2021, 70, 1884-1893.	12.1	233
9	British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut, 2020, 69, 984-990.	12.1	232
10	MicroRNAs: new players in IBD. Gut, 2015, 64, 504-513.	12.1	223
11	Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease. Nature Communications, 2016, 7, 13507.	12.8	191
12	Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. Gastroenterology, 2015, 149, 1716-1730.	1.3	180
13	Inflammatory Bowel Disease Associates with Proinflammatory Potential of the Immunoglobulin G Glycome. Inflammatory Bowel Diseases, 2015, 21, 1.	1.9	161
14	Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7. Nature Genetics, 2017, 49, 186-192.	21.4	153
15	Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut, 2021, 70, 865-875.	12.1	153
16	Genome-wide methylation profiling in CrohnÊ¼s disease identifies altered epigenetic regulation of key host defense mechanisms including the Th17 pathway. Inflammatory Bowel Diseases, 2012, 18, 889-899.	1.9	152
17	Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis. Autoimmunity Reviews, 2022, 21, 102927.	5.8	132
18	Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. JAMA - Journal of the American Medical Association, 2019, 321, 773.	7.4	129

#	Article	IF	Citations
19	The role of glycosylation in IBD. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 588-600.	17.8	123
20	Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases. Gastroenterology, 2018, 154, 1320-1333.e10.	1.3	116
21	SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. The Lancet Gastroenterology and Hepatology, 2021, 6, 218-224.	8.1	111
22	COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. The Lancet Gastroenterology and Hepatology, 2022, 7, 342-352.	8.1	100
23	Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for adults with Crohn's disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 660-669.	3.7	96
24	Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. Nature Genetics, 2021, 53, 1543-1552.	21.4	96
25	Massively parallel variant characterization identifies NUDT15 alleles associated with thiopurine toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 5394-5401.	7.1	95
26	The Diagnostic Accuracy of Fecal Calprotectin During the Investigation of Suspected Pediatric Inflammatory Bowel Disease. American Journal of Gastroenterology, 2012, 107, 941-949.	0.4	94
27	Dietary Manipulation of Oncogenic MicroRNA Expression in Human Rectal Mucosa: A Randomized Trial. Cancer Prevention Research, 2014, 7, 786-795.	1.5	94
28	Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2016, 1, 273-282.	8.1	91
29	Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases. American Journal of Gastroenterology, 2016, 111, 1796-1805.	0.4	88
30	Relapse after withdrawal from antiâ€<scp>TNF</scp> therapy for inflammatory bowel disease: an observational study, plus systematic review and metaâ€analysis. Alimentary Pharmacology and Therapeutics, 2016, 43, 910-923.	3.7	87
31	Two-stage Genome-wide Methylation Profiling in Childhood-onset CrohnÊ¼s Disease Implicates Epigenetic Alterations at the VMP1/MIR21 and HLA Loci. Inflammatory Bowel Diseases, 2014, 20, 1784-1793.	1.9	84
32	Plasma N-Glycan Signatures Are Associated With Features ofÂInflammatory Bowel Diseases. Gastroenterology, 2018, 155, 829-843.	1.3	80
33	Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience. Journal of Crohn's and Colitis, 2020, 14, 1385-1393.	1.3	74
34	MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammation. Mucosal Immunology, 2018, 11, 120-130.	6.0	70
35	Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. Lancet Rheumatology, The, 2022, 4, e490-e506.	3.9	61
36	Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Alimentary Pharmacology and Therapeutics, 2014, 40, 1313-1323.	3.7	55

#	Article	IF	Citations
37	A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and metaâ€analysis. Alimentary Pharmacology and Therapeutics, 2013, 38, 1255-1266.	3.7	54
38	Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 2269-2276.e4.	4.4	48
39	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nature Communications, 2022, 13, 1379.	12.8	48
40	Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16â€“50years. Journal of Crohn's and Colitis, 2014, 9, 41-9.	1.3	43
41	Systematic review: the use of thiopurines or antiâ€<scp>TNF</scp> in postâ€operative Crohn's disease maintenance â€“ progress and prospects. Alimentary Pharmacology and Therapeutics, 2014, 39, 1253-1265.	3.7	43
42	The Impact of NOD2 Variants on Fecal Microbiota in Crohnâ€™s Disease and Controls Without Gastrointestinal Disease. Inflammatory Bowel Diseases, 2018, 24, 583-592.	1.9	40
43	Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. Journal of Crohn's and Colitis, 2022, 16, 389-397.	1.3	39
44	Serum C-reactive Protein and CRP Genotype in Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 596-605.	1.9	38
45	Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic. Frontline Gastroenterology, 2020, 11, 343-350.	1.8	37
46	Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease. Journal of Crohn's and Colitis, 2021, 15, 699-708.	1.3	36
47	Promoter methylation of the MGAT3 and BACH2 genes correlates with the composition of the immunoglobulin G glycome in inflammatory bowel disease. Clinical Epigenetics, 2018, 10, 75.	4.1	32
48	Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. Alimentary Pharmacology and Therapeutics, 2018, 47, 1103-1116.	3.7	31
49	Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut, 2020, 69, gutjnl-2020-321927.	12.1	28
50	Optimisation of hepatocellular carcinoma surveillance in patients with viral hepatitis: a quality improvement study. Internal Medicine Journal, 2013, 43, 772-777.	0.8	26
51	Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease. Internal Medicine Journal, 2013, 43, 278-286.	0.8	25
52	Common polygenic variation in coeliac disease and confirmation of ZNF335 and NIFA as disease susceptibility loci. European Journal of Human Genetics, 2016, 24, 291-297.	2.8	25
53	DNA methylation in a Scottish family multiply affected by bipolar disorder and major depressive disorder. Clinical Epigenetics, 2016, 8, 5.	4.1	23
54	Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. The Lancet Gastroenterology and Hepatology, 2021, 6, 271-281.	8.1	23

#	Article	IF	Citations
55	Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients. Journal of Crohn's and Colitis, 2022, 16, 591-600.	1.3	23
56	The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohnâ€™s Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation. Journal of Crohn's and Colitis, 2021, 15, 800-812.	1.3	22
57	Faecal Calprotectin and Magnetic Resonance Enterography in Ileal Crohnâ€™s Disease: Correlations Between Disease Activity and Long-Term Follow-Up. Journal of Crohn's and Colitis, 2019, 13, 442-450.	1.3	20
58	Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic. Gut, 2022, 71, 1426-1439.	12.1	20
59	Rootâ€cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2021, 53, 291-301.	3.7	19
60	Incidence and prevalence of inflammatory bowel disease in Devon, UK. Frontline Gastroenterology, 2021, 12, 461-470.	1.8	18
61	Whole Blood Profiling of T-cell-Derived microRNA Allows the Development of Prognostic models in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2020, 14, 1724-1733.	1.3	16
62	Nationwide linkage analysis in Scotland to assess mortality following hospital admission for Crohnâ€™s disease: 1998â€“2000. Alimentary Pharmacology and Therapeutics, 2012, 35, 142-153.	3.7	15
63	Changes to Serum Sample Tube and Processing Methodology Does Not Cause Inter-Individual Variation in Automated Whole Serum N-Glycan Profiling in Health and Disease. PLoS ONE, 2015, 10, e0123028.	2.5	15
64	GWAS of stool frequency provides insights into gastrointestinal motility and irritable bowel syndrome. Cell Genomics, 2021, 1, 100069.	6.5	15
65	Quality improvement project identifies factors associated with delay in IBD diagnosis. Alimentary Pharmacology and Therapeutics, 2020, 52, 471-480.	3.7	14
66	Comparison of mortality following hospitalisation for ulcerative colitis in Scotland between 1998â€“2000 and 2007â€“2009. Alimentary Pharmacology and Therapeutics, 2014, 39, 1387-1397.	3.7	13
67	Predicting outcomes in acute severe ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2015, 9, 405-415.	3.0	12
68	Colonoscopy quality with Entonox^{Â®} vs intravenous conscious sedation: 18608 colonoscopy retrospective study. World Journal of Gastrointestinal Endoscopy, 2017, 9, 471.	1.2	10
69	OP013 HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohnâ€™s disease. Journal of Crohn's and Colitis, 2018, 12, S009-S010.	1.3	9
70	Validating the positivity thresholds of drugâ€tolerant antiâ€infliximab and antiâ€adalimumab antibody assays. Alimentary Pharmacology and Therapeutics, 2021, 53, 128-137.	3.7	9
71	A comprehensive high cost drugs dataset from the NHS in England - An OpenSAFELY-TPP Short Data Report. Wellcome Open Research, 0, 6, 360.	1.8	8
72	Atypical paraneoplastic pemphigus secondary to endometrial carcinoma with no mucosal involvement. Clinical and Experimental Dermatology, 2009, 34, e130-e133.	1.3	7

#	Article	IF	Citations
73	Patient-led Remote IntraCapillary pharmacoKinetic Sampling (fingerPRICKS) for Therapeutic Drug Monitoring in patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2022, 16, 190-198.	1.3	7
74	Systematic review with metaâ€analysis: effect of inflammatory bowel disease therapy on lipid levels. Alimentary Pharmacology and Therapeutics, 2021, 54, 999-1012.	3.7	7
75	Letter: risk of severe COVIDâ€19 outcomes associated with inflammatory bowel disease medicationsâ€”reassuring insights from the United Kingdom PREPAREâ€IBD multicentre cohort study. Alimentary Pharmacology and Therapeutics, 2021, 53, 1236-1240.	3.7	7
76	Exploring the hidden heritability of inflammatory bowel disease. Gut, 2011, 60, 1447-1448.	12.1	6
77	Editorial: which iron preparation for patients with IBD?. Alimentary Pharmacology and Therapeutics, 2017, 46, 194-195.	3.7	6
78	Practice pattern variability in the management of acute severe colitis: a UK provider survey. Frontline Gastroenterology, 2020, 11, 272-279.	1.8	6
79	Root-cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2021, 53, 291-301.	3.7	5
80	Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study. Alimentary Pharmacology and Therapeutics, 2021, 53, 1236-1240.	3.7	5
81	Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity. Gut, 2023, 72, 410-412.	12.1	5
82	Understanding <scp>antiâ€TNF</scp> treatment failure: does serum triiodothyronineâ€toâ€thyroxine (<scp>T3</scp>/<scp>T4</scp>) ratio predict therapeutic outcome to <scp>antiâ€TNF</scp> therapies in biologicâ€naÃ¯ve patients with active luminal Crohn's disease?. Alimentary Pharmacology and Therapeutics, 2022, 56, 783-793.	3.7	5
83	Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study. Archives of Disease in Childhood, 2020, 105, 957-963.	1.9	4
84	A randomised, double-blind, parallel-group trial to assess mercaptopurine versus placebo to prevent or delay recurrence of Crohnâ€™s disease following surgical resection (TOPPIC). Efficacy and Mechanism Evaluation, 2017, 4, 1-60.	0.7	4
85	Ambulatory care management of 69 patients with acute severe ulcerative colitis in comparison to 695 inpatients: insights from a multicentre UK cohort study. BMJ Open Gastroenterology, 2022, 9, e000763.	2.7	4
86	PTH-082â€…Serum Calprotectin: A Novel Biomarker to Predict Outcome in Acute Severe Ulcerative Colitis?. Gut, 2013, 62, A244.2-A245.	12.1	3
87	DOP28 Understanding the molecular mechanisms of anti-TNF treatment failure in patients with Crohnâ€™s disease: A pilot serum proteomic analysis of the PANTS cohort. Journal of Crohn's and Colitis, 2020, 14, S067-S068.	1.3	3
88	Establishment of a validated central reading system for ileocolonoscopy in an academic setting. Gut, 2022, 71, 661-664.	12.1	3
89	Letter: azathioprineâ€induced pancreatitis and subsequent tolerance of mercaptopurine â€“ authors' reply. Alimentary Pharmacology and Therapeutics, 2014, 39, 440-441.	3.7	2
90	Editorial: early corticosteroids in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2014, 40, 727-727.	3.7	2

#	Article	IF	Citations
91	Interaction Between NOD2 and Smoking in the Pathogenesis of Crohn's Disease. EBioMedicine, 2017, 21, 49-50.	6.1	2
92	Immunomodulator and Biologic Combination Therapy in IBD: The Debate That Just Wonâ€™t Go Away?. Journal of Crohn's and Colitis, 2020, 14, 1343-1344.	1.3	2
93	Letter: online search trends suggest patient concerns around immunosuppression use in inflammatory bowel disease during COVIDâ€19 in the United Kingdom. Alimentary Pharmacology and Therapeutics, 2020, 52, 937-939.	3.7	2
94	SARS-CoV-2 vaccination for patients with inflammatory bowel disease â€“ Authors' reply. The Lancet Gastroenterology and Hepatology, 2021, 6, 523-524.	8.1	2
95	OFR-8â€…Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines. , 2021, , .		2
96	PTU-123â€…Acute severe ulcerative colitis: the last 12â€…years in Edinburgh: Abstract PTU-123 Figure 1. Gut, 2012, 61, A235.2-A236.	12.1	1
97	Letter: faecal calprotectin and lactoferrin â€“ accurate biomarkers in postâ€operative Crohn's disease â€“ authors' reply. Alimentary Pharmacology and Therapeutics, 2014, 40, 323-323.	3.7	1
98	Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel diseaseâ€”getting to the root. Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 337-338.	3.7	1
99	A guide to out of programme training and experience in Australia. British Journal of Hospital Medicine (London, England: 2005), 2011, 72, M141-M144.	0.5	0
100	OC-166â€…Predictive factors of disease relapse following thiopurine withdrawal for sustained clinical remission of IBD: Abstract OC-166 Figure 1. Gut, 2012, 61, A71.2-A72.	12.1	0
101	Mortality in patients hospitalised with Crohnâ€™s disease: authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2012, 35, 397-398.	3.7	0
102	PWE-108â€…Assessment of the Mucosal Microbiota in Inflammatory Bowel Disease. Gut, 2013, 62, A174.2-A175.	12.1	0
103	PTH-079â€…Thiopurine Withdrawal for Sustained Remission in IBD: A UK Multicentre Study. Gut, 2013, 62, A243.1-A243.	12.1	0
104	A plea for TDM-based optimisation for treatment of Crohn's disease â€“ Authors' reply. The Lancet Gastroenterology and Hepatology, 2017, 2, 81-82.	8.1	0
105	Editorial: accelerated infliximab inductionâ€”it's time to settle the debate! Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 1061-1062.	3.7	0
106	PWE-010â€…Introduction of a primary care dietetics service for functional gut disorders. , 2019, , .		0
107	Reply. Clinical Gastroenterology and Hepatology, 2020, 18, 526.	4.4	0
108	DOP69 Tofacitinib in ulcerative colitis: Early â€˜real-worldâ€™ experience from four UK tertiary centres. Journal of Crohn's and Colitis, 2020, 14, S106-S106.	1.3	0

#	Article	IF	Citations
109	P92â€...Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multi-centre UK experience. , 2021, , .		0
110	Integrating a treat to target approach into clinical practice in 2020. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 6-7.	2.8	0
111	P401 Risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications: Reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study. Journal of Crohn's and Colitis, 2021, 15, S409-S410.	1.3	0
112	P387 Depression in biologic-treated patients with inflammatory bowel disease during the COVID19 pandemic. Journal of Crohn's and Colitis, 2021, 15, S398-S399.	1.3	0
113	Response to â€˜Clinical Efficacy of Tofacitinib in Moderate to Severe Ulcerative Colitisâ€™. Journal of Crohn's and Colitis, 2021, 15, 1775-1776.	1.3	0
114	Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis. British Journal of Hospital Medicine (London, England: 2005), 2021, 82, 1-11.	0.5	0
115	The UK IBD Registry COVID-19 Risk Tool; Patient Generated Data Can Improve the Hospital Record. SSRN Electronic Journal, 0, , .	0.4	0
116	Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis. Gastrointestinal Nursing, 2022, 20, 34-41.	0.1	0